Literature DB >> 26548748

Indeterminate Single Thyroid Nodule: Synergistic Impact of Mutational Markers and Sonographic Features in Triaging Patients to Appropriate Surgery.

Luigi De Napoli1, Sohail Bakkar1, Carlo Enrico Ambrosini1, Gabriele Materazzi1, Agnese Proietti2, Elisabetta Macerola2, Fulvio Basolo2, Paolo Miccoli1.   

Abstract

BACKGROUND: Patients labeled as having indeterminate thyroid nodular disease following fine-needle aspiration cytology are at risk of non-optimal initial surgery: an overly radical total thyroidectomy, or an unnecessary two-stage operation. The objective of this study was to assess the impact of combining mutational markers and ultrasonographic (US) features preoperatively on predicting the risk of malignancy in patients with indeterminate nodules, thereby offering them a tailored initial surgical intervention.
METHODS: The records of 258 patients who underwent conventional total thyroidectomy for single nodules reported as suspicious for a follicular neoplasm (Bethesda category IV) in a four-year period were reviewed. Main issues addressed included: certain US findings (individually and in combination), mutational markers (BRAF and NRAS), and combinations of both. Correlation of these with malignancy was assessed, as was their ability to predict malignancy. The usefulness of combining the absence of suspicious sonographic features and the absence of mutational markers was also evaluated.
RESULTS: Among the 258 patients with an indeterminate diagnosis, only 90 lesions were found to be malignant. The sonographic features that correlated significantly with malignancy were irregular margins, microcalcifications, and a "taller than wide" shape. The presence of irregular margins was the feature with the highest positive predictive value. Combinations of two or more features were always associated with predictivity in excess of 90%, and at times at 100%. NRAS mutation was the most common gene alteration. Both BRAF and NRAS mutations were mutually exclusive and correlated significantly with malignancy. Their predictivity of malignancy was high, particularly when combined with suspicious sonographic features (100%). The major limitation of both suspicious sonographic features and/or mutational markers was their low occurrence in malignancy. The absence of both mutational markers and suspicious sonographic features proved extremely useful in tailoring surgical strategy, as it could have ultimately spared 143/258 patients (55%) an overly radical thyroidectomy.
CONCLUSION: The preoperative utility of mutational markers and sonographic features in combination has a synergistic impact. It can predict the risk of malignancy with high accuracy, properly triaging patients to appropriate surgery.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26548748     DOI: 10.1089/thy.2015.0311

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  13 in total

1.  Diagnostic performance of ATA, BTA and TIRADS sonographic patterns in the prediction of malignancy in histologically proven thyroid nodules.

Authors:  Chiaw Ling Chng; Hong Chang Tan; Chow Wei Too; Wei Ying Lim; Priscilla Pei Sze Chiam; Ling Zhu; Nivedita Vikas Nadkarni; Adoree Yi Ying Lim
Journal:  Singapore Med J       Date:  2018-05-18       Impact factor: 1.858

2.  The Role of Molecular Diagnostics in the Management of Indeterminate Thyroid Nodules.

Authors:  Joanna Klubo-Gwiezdzinska; Leonard Wartofsky
Journal:  J Clin Endocrinol Metab       Date:  2018-09-01       Impact factor: 5.958

Review 3.  Tailored surgery according to molecular analysis in differentiated thyroid carcinomas.

Authors:  Paolo Miccoli; Gabriele Materazzi; Elisabetta Macerola; Sohail Bakkar
Journal:  Gland Surg       Date:  2018-08

4.  Underestimated risk of cancer in solitary thyroid nodules ≥3 cm reported as benign.

Authors:  Sohail Bakkar; Anello Marcello Poma; Caterina Corsini; Mario Miccoli; Carlo Enrico Ambrosini; Paolo Miccoli
Journal:  Langenbecks Arch Surg       Date:  2017-07-08       Impact factor: 3.445

5.  Transoral thyroidectomy: a viable surgical option with unprecedented complications-a case series.

Authors:  S Bakkar; M Al Hyari; M Naghawi; C Corsini; P Miccoli
Journal:  J Endocrinol Invest       Date:  2017-12-14       Impact factor: 4.256

6.  BRAFV600E mutation: a potential predictor of more than a Sistrunk's procedure in patients with thyroglossal duct cyst carcinoma and a normal thyroid gland.

Authors:  Sohail Bakkar; Elisabetta Macerola; Qusai Aljarrah; Agnese Proietti; Gabriele Materazzi; Fulvio Basolo; Paolo Miccoli
Journal:  Updates Surg       Date:  2019-10-04

7.  Indeterminate Thyroid Nodules: A Pragmatic Approach.

Authors:  Aly Bernard Khalil; Roberto Dina; Karim Meeran; Ali M Bakir; Saf Naqvi; Alia Al Tikritti; Nader Lessan; Maha T Barakat
Journal:  Eur Thyroid J       Date:  2017-11-21

8.  Frequency and Significance of Ras, Tert Promoter, and Braf Mutations in Cytologically Indeterminate Thyroid Nodules: A Monocentric Case Series at a Tertiary-Level Endocrinology Unit.

Authors:  Simona Censi; Elisabetta Cavedon; Loris Bertazza; Francesca Galuppini; Sara Watutantrige-Fernando; Paola De Lazzari; Davide Nacamulli; Gianmaria Pennelli; Ambrogio Fassina; Maurizio Iacobone; Eric Casal Ide; Federica Vianello; Susi Barollo; Caterina Mian
Journal:  Front Endocrinol (Lausanne)       Date:  2017-10-16       Impact factor: 5.555

9.  Ultrasound characteristics of thyroid nodules facilitate interpretation of the malignant risk of Bethesda system III/IV thyroid nodules and inform therapeutic schedule.

Authors:  Fu Li; Denghua Pan; Yuquan Wu; Jinbo Peng; Qing Li; Xiaolong Gui; Wei Ma; Hong Yang; Yun He; Junqiang Chen
Journal:  Diagn Cytopathol       Date:  2019-06-18       Impact factor: 1.582

Review 10.  Correlations between Molecular Landscape and Sonographic Image of Different Variants of Papillary Thyroid Carcinoma.

Authors:  Andrzej Lewiński; Zbigniew Adamczewski; Arkadiusz Zygmunt; Leszek Markuszewski; Małgorzata Karbownik-Lewińska; Magdalena Stasiak
Journal:  J Clin Med       Date:  2019-11-08       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.